<DOC>
	<DOC>NCT02084953</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-791325 has an effect on the electrocardiogram (ECG) interval QT corrected for Fridericia's method (QTcF).</brief_summary>
	<brief_title>Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects</brief_title>
	<detailed_description>Primary Purpose: Other: This Phase 1 study is a clinical pharmacology thorough QT study.</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy men and women, ages 18 to 49 yr old BMI 18 to 32 Women must not be pregnant or breastfeeding Any significant acute or chronic medical illness A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) History of hypokalemia, personal history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age History of biliary disorders, including Gilbert's disease or DubinJohnson disease Inability to swallow multiple tablets consecutively Any of the following on 12lead electrocardiogram (ECG) prior to study drug administration: PR ≥ 210 msec, QRS ≥ 120 msec, QT ≥ 500 msec, QTcF ≥ 450 msec, Heart Rate (HR) &lt; 45 bpm Second or third degree heart block prior to study drug Positive urine screen for drugs of abuse Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV)1, 2 antibody Any of the following lab results outside of the ranges specified below prior to dosing: Alanine aminotransferase (ALT) &gt; upper limit of normal (ULN), Aspartate aminotransferase (AST) &gt; ULN, Total bilirubin &gt; ULN, Direct bilirubin &gt; ULN, Creatinine &gt; ULN, Serum potassium &lt; lower limit of normal (LLN), Serum magnesium &lt; LLN History of allergy to Moxifloxacin, BMS791325, nonstructural protein 5B (NS5B) nonnucleoside inhibitors or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>